Acute Myeloid Leukaemia Treatment Pathways:  a Detailed Costing Study Example

H.I. Wang; C. Godfrey; S. Parrott; D. Howell; Russell Patmore; E. Roman; A. Jack; A. Smith

doi:10.1016/j.jval.2012.08.312

Acute Myeloid Leukaemia Treatment Pathways: a Detailed Costing Study Example

H.I. Wang, C. Godfrey, S. Parrott, D. Howell, Russell Patmore, E. Roman, A. Jack, A. Smith

Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Acute Myeloid Leukaemia (AML) can be diagnosed at any age and accounts for around a third of all leukaemia diagnoses. Treatment, which can be given with supportive and/or curative intent, is expensive with costly medical interventions and lengthy hospitalization (often due to complications). Despite this, little is known about its lifetime economic burden with few studies attempting to cost the entire treatment pathway. This investigation aimed to address these issues by estimating the phase-specific and lifetime pathway costs of a UK cohort of AML patients.

Original language	English
Article number	PCN14
Pages (from-to)	A655
Journal	Value in Health
Volume	15
Issue number	7
DOIs	https://doi.org/10.1016/j.jval.2012.08.312
Publication status	Published - 1 Nov 2012
Event	ISPOR 15th Annual European Congress - Berlin, Germany Duration: 3 Nov 2012 → 7 Nov 2012

Bibliographical note

doi: 10.1016/j.jval.2012.08.312

Access to Document

10.1016/j.jval.2012.08.312

Cite this

@article{d75930db3b1f476f800f4c3bba0480b9,

title = "Acute Myeloid Leukaemia Treatment Pathways: a Detailed Costing Study Example",

abstract = "Acute Myeloid Leukaemia (AML) can be diagnosed at any age and accounts for around a third of all leukaemia diagnoses. Treatment, which can be given with supportive and/or curative intent, is expensive with costly medical interventions and lengthy hospitalization (often due to complications). Despite this, little is known about its lifetime economic burden with few studies attempting to cost the entire treatment pathway. This investigation aimed to address these issues by estimating the phase-specific and lifetime pathway costs of a UK cohort of AML patients.",

author = "H.I. Wang and C. Godfrey and S. Parrott and D. Howell and Russell Patmore and E. Roman and A. Jack and A. Smith",

note = "doi: 10.1016/j.jval.2012.08.312; ISPOR 15th Annual European Congress ; Conference date: 03-11-2012 Through 07-11-2012",

year = "2012",

month = nov,

day = "1",

doi = "10.1016/j.jval.2012.08.312",

language = "English",

volume = "15",

pages = "A655",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier",

number = "7",

}

TY - JOUR

T1 - Acute Myeloid Leukaemia Treatment Pathways

T2 - ISPOR 15th Annual European Congress

AU - Wang, H.I.

AU - Godfrey, C.

AU - Parrott, S.

AU - Howell, D.

AU - Patmore, Russell

AU - Roman, E.

AU - Jack, A.

AU - Smith, A.

N1 - doi: 10.1016/j.jval.2012.08.312

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Acute Myeloid Leukaemia (AML) can be diagnosed at any age and accounts for around a third of all leukaemia diagnoses. Treatment, which can be given with supportive and/or curative intent, is expensive with costly medical interventions and lengthy hospitalization (often due to complications). Despite this, little is known about its lifetime economic burden with few studies attempting to cost the entire treatment pathway. This investigation aimed to address these issues by estimating the phase-specific and lifetime pathway costs of a UK cohort of AML patients.

AB - Acute Myeloid Leukaemia (AML) can be diagnosed at any age and accounts for around a third of all leukaemia diagnoses. Treatment, which can be given with supportive and/or curative intent, is expensive with costly medical interventions and lengthy hospitalization (often due to complications). Despite this, little is known about its lifetime economic burden with few studies attempting to cost the entire treatment pathway. This investigation aimed to address these issues by estimating the phase-specific and lifetime pathway costs of a UK cohort of AML patients.

U2 - 10.1016/j.jval.2012.08.312

DO - 10.1016/j.jval.2012.08.312

M3 - Article

SN - 1098-3015

VL - 15

SP - A655

JO - Value in Health

JF - Value in Health

IS - 7

M1 - PCN14

Y2 - 3 November 2012 through 7 November 2012

ER -